30 closest matches · ranked by relevance
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
Vitamin D Deficiency
Primary: The Blood Levels of Calcium at the 24th Month of Following up. — 2.31; 2.33 mmol/L — p=0.117
Chronic Kidney Disease
Primary: Calcium Balance — 61; 508 mg/d calcium
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Chronic Kidney Disease
Primary: The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels — 93; 57; 12; 45 participants
Chronic Kidney Disease · Vitamin D Deficiency · Coronary Calcification
Primary: Coronary Artery (CAC) Score Progression — 74.38; 106.32 Agatston units
Chronic Kidney Disease
Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml
Secondary Hyperparathyroidism
Primary: Change in FGF-23 Level — 16; 41 percentage change from baseline
Secondary Hyperparathyroidism
Primary: Percent Change From Baseline in Parathyroid Hormone (PTH) During the Efficacy Period — -53.6; -55.6; -50.8 percent change
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Secondary Hyperparathyroidism · Chronic Kidney Disease Stage V · Cardiac Morbidity
Primary: Percentage of Participants Achieving an Intact Parathyroid Hormone (iPTH) Level Within the Target Range — 28.4; 43.3; 35.8; 38.8 percentage of participants
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Confirmed Hypercalcemia — 3; 1 participants — p=0.36
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]
Renal Impairment
Primary: Number of Participants With Clinically Significant Hypocalcemia — 1; 2 participants
Renal Osteodystrophy
Primary: Percent Reduction in PTH — 27; 10 % change in PTH baseline to 3 months
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL
Anemia · Secondary Hyperparathyroidism
Primary: Number of Participants With a Mean Intact Parathyroid Hormone Value Between 150 and 300 pg/mL and a Calcium - Phosphorus Product Value < 55 mg^2/dL^2 — 30 Participants
Chronic Kidney Disease Stage 3 and 4
Primary: Part 1: Paricalcitol Maximum Observed Plasma Concentration (Cmax) — 0.13 ng/mL
Chronic Kidney Disease Mineral and Bone Disorder · Renal Osteodystrophy · Vascular Calcification
Primary: Percent Change in PTH Levels — 0; -54.14; -64.04 percentage of change in PTH levels
Hyperphosphatemia
Primary: Change From Baseline in Serum Phosphorus at Week 8 — 2.090; 2.095; 0.010; -0.200 mmol/L — p=<0.0001
Chronic Kidney Disease (CKD) · End-stage Renal Disease (ESRD)
Primary: Monocyte Protein Expression — 34110; 38540; 1359; 1360 relative fluorescence units
Secondary Hyperparathyroidism Due to Renal Causes · Vitamin D Insufficiency · CKD Stage 3
Primary: Incidence and Severity of Treatment-Emergent Adverse Events (TEAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. — 39; 12; 13; 10…
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
End-Stage Renal Disease · Secondary Hyperparathyroidism
Primary: Percentage of Subjects With Hypercalcemia — 15.3 percentage of participants
Moderate to Severe Secondary Hyperparathyroidism · Stage 5 Chronic Kidney Diseases
Primary: Mean Erythropoietin Dose Per Visit — 35.8; 22.2; 22.7; 4.7 µg
Chronic Kidney Disease
Primary: Serum Phosphorus — 3.9; 4.2 mg/dL
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: Number of Adverse Events (AE) — 109; 50; 63 participants
Secondary Hyperparathyroidism · Chronic Renal Insufficiency
Primary: Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase — 15; 5 Participants — p=0.006
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04